Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 0.88 |
| ▸ | CCNH | P51946 | 19/20 | 0.88 |
| ▸ | CCNK | O75909 | 17/20 | 0.88 |
| ▸ | CDK9 | P50750 | 16/20 | 0.88 |
| ▸ | CDK12 | Q9NYV4 | 16/20 | 0.88 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.88 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.88 |
| ▸ | CDK2 | P24941 | 13/20 | 0.68 |
| ▸ | CDK13 | Q14004 | 13/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.67 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583583 | 0.94 | CDK7 (1.00) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17151736 | 0.94 | CDK7 (0.88) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17151964 | 0.94 | CDK7 (1.00) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL18069741 | 0.92 | CDK7 (0.87) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17150548 | 0.91 | CDK7 (0.84) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17150722 | 0.91 | CDK7 (0.84) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17150614 | 0.87 | CDK7 (0.73) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL20412363 | 0.87 | CDK7 (0.89) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL17150651 | 0.86 | CDK7 (0.87) | CDK7CCNHCCNKCDK9CDK12 | |
| SCHEMBL18047286 | 0.86 | CDK7 (1.00) | CDK7CCNHCCNKCDK9CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| WO-2019035866-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3126352-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| WO-2015154038-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885CCNK 8/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885CCNK 8/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885CCNK 8/4885 |
| US-20200197392-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | CDK7, CDK17, MTOR | CDK7 1/4885CCNH 16/4885CCNK 12/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885CCNK 8/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 31/4885CCNK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.